Climb Bio Inc (CLYM NASDAQ) stock market data APIs
$1.2701
0(0%)
as of July 3, 2025
Try our APIs with
free plan!
Climb Bio Inc Financial Data Overview
Price chart is built with
Anychart
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Prev. Close
1.2701
Open
1.2723
High
1.3103
Low
1.2466
52 wk Range
1.05-9.21
Market Cap
85 821 K
Shares Outstanding
67 576 K
EPS
-0.31
Beta
-0.113
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Climb Bio Inc data using free add-ons & libraries
Get Climb Bio Inc Fundamental Data
Climb Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-14
- EPS/Forecast: -0.15
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Climb Bio Inc News
New
Climb Bio appoints Cindy Driscoll as SVP Finance and principal financial officer
Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotech company with a market capitalization of $81 million, announced the appointment of Cindy Driscoll as Senior Vice President, Finance, effective Ju...
Climb Bio appoints Edgar D. Charles as Chief Medical Officer
Climb Bio (NASDAQ:CLYM [https://seekingalpha.com/symbol/CLYM]) has announced the appointments [https://seekingalpha.com/pr/20140329-climb-bio-appoints-edgar-d-charles-m-d-msc-as-chief-medical-officer]...
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, to...
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX
By Exec Edge Editorial Staff Exec Edge today announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates. Exec Edge Researc...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
